Heart Failure with Preserved Ejection Fraction and Geriatric Cardiology

Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure among older individuals, and our lab strives to understand the pathophysiologic mechanism of exercise intolerance associated with HFpEF. We investigate a multi-system, gero-centric approach to understanding HFpEF. The lab has also leveraged big-data and machine-learning based approaches to better phenomap individuals with HFpEF, a heterogenous clinical condition. Our lab has many ongoing HFpEF clinical trials, ranging from single-center, investigator-initiated research to large scale, multicenter trials. We investigate strategies to improve outcomes for patients with HFpEF, including novel pharmacotherapeutics, medical devices, and exercise rehabilitation.

Ongoing Clinical Trials

  1. Research study to look at how well semaglutide works in people living with heart failure, obesity, and type 2 diabetes (STEP-HFpEF DM Trial).
  2. Research study to investigate how well semaglutide works in people living with heart failure and obesity (STEP-HFpEF trial)
  3. A study of LY3540378 in participants with worsening chronic heart failure with preserved ejection fraction (RELAX-LA)
  4. A study of tirzepatide in patients with heart failure with preserved ejection fraction and obesity (SUMMIT)
  5. Physical rehabilitation for older patients with acute heart failure with preserved ejection fraction (REHAB-HFpEF)
  6. Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients With Chronic Heart Failure (ALLAY-HF)
  7. COOrdinating CaRDIology CliNics Randomized Trial of Interventions to Improve OutcomEs (COORDINATE) ā€“ diabetes
  8. Safety and efficacy of AT-001 in patients with diabetic cardiomyopathy
  9. MyoVista wavECG clinical validation study versus low eā€™ on echocardiogram
  10. A crossover, double-blinded, two-period, two-treatment, two-sequence, double-dummy study to evaluate the effects of extended release (ER) torsemide in patients with chronic Congestive Heart Failure (CHF) and symptoms of overactive bladder (OAB)
  11. Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation
  12. A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)